UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
Commission File Number:
(Exact name of registrant as specified in charter)
(State or other jurisdiction of incorporation or organization) |
(IRS Employer Identification No.) |
(Address of principal executive offices, including zip code)
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
SECTION 7 - REGULATION FD
Item 7.01. | Regulation FD Disclosure. |
On April 14, 2021, Amedisys, Inc. (the “Company”) issued a press release announcing that it has signed a definitive agreement to acquire regulatory assets that allow the Company to conduct home health care operations in Randolph County, North Carolina, a copy of which is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K.
The information included in this Current Report on Form 8-K under this Item 7.01 (including Exhibit 99.1 hereto) is being “furnished” and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of Section 18, nor shall it be incorporated by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. The information included in this Current Report on Form 8-K under this Item 7.01 (including Exhibit 99.1 hereto) will not be deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD.
SECTION 9 - FINANCIAL STATEMENTS AND EXHIBITS
Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits.
Exhibit Number |
Description | |
99.1 | Press Release dated April 14, 2021 | |
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
AMEDISYS, INC. | ||
By: | /s/ Paul B. Kusserow | |
Paul B. Kusserow | ||
Chief Executive Officer and Chairman of the Board |
DATE: | April 14, 2021 |
Exhibit 99.1
Contact:
Kendra Kimmons Vice President of Marketing & Communications 225-299-3708 kendra.kimmons@amedisys.com |
Amedisys to Acquire Randolph County Home Health Regulatory Asset
BATON ROUGE, La., April 14, 2021 Amedisys, Inc. (NASDAQ: AMED), a leading provider of quality home health, hospice and personal care, has signed a definitive agreement to acquire regulatory assets that allow the Company to conduct home health care operations in Randolph County, N.C.
Under the terms of the agreement, expected to close April 30, 2021, Amedisys will acquire the right to operate certified home health care services in Randolph County, N.C., and surrounding areas within a 50-mile radius, including Montgomery County. The service area provides access to 31,000 Medicare and Medicare Advantage enrollees.
Were honored to be able to offer our compassionate, clinically distinct care to more patients in more places, stated Home Health President Teonie Aurelio. Expanding our footprint into this key market further establishes Amedisys as Americas solution for aging in place.
Upon close, Amedisys will open a start-up care center to serve patients in the newly acquired service area. Amedisys is the second largest provider of home health care in the United States with 320 locations across 34 states.
About Amedisys:
Amedisys, Inc. is a leading healthcare at home company delivering personalized home health, hospice and personal care. Amedisys is focused on delivering the care that is best for our patients, whether that is home-based personal care; recovery and rehabilitation after an operation or injury; care focused on empowering them to manage a chronic disease; or hospice care at the end of life. More than 2,900 hospitals and 78,000 physicians nationwide have chosen Amedisys as a partner in post-acute care. Founded in 1982, headquartered in Baton Rouge, LA with an executive office in Nashville, TN, Amedisys is a publicly held company. With approximately 21,000 employees, in 514 care centers in 39 states and the District of Columbia, Amedisys is dedicated to delivering the highest quality of care to the doorsteps of more than 418,000 patients in need every year. For more information about the Company, please visit: www.amedisys.com.
Forward-Looking Statements:
When included in this press release, words like believes, belief, expects, plans, anticipates, intends, projects, estimates, may, might, would, should, will and similar expressions are intended to identify forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a variety of risks and uncertainties that could cause actual results to differ materially from those described therein. These risks and uncertainties include, but are not limited to the following: the
impact of the novel coronavirus pandemic (COVID-19), including the measures that have been and may be taken by governmental authorities to mitigate it, on our business, financial condition and results of operations, changes in or our failure to comply with existing federal and state laws or regulations or the inability to comply with new government regulations on a timely basis, changes in Medicare and other medical payment levels, our ability to open care centers, acquire additional care centers and integrate and operate these care centers effectively, competition in the healthcare industry, changes in the case mix of patients and payment methodologies, changes in estimates and judgments associated with critical accounting policies, our ability to maintain or establish new patient referral sources, our ability to attract and retain qualified personnel, our ability to keep our patients and employees safe, changes in payments and covered services by federal and state governments, future cost containment initiatives undertaken by third-party payors, our access to financing, our ability to meet debt service requirements and comply with covenants in debt agreements, business disruptions due to natural disasters or acts of terrorism, widespread protest or civil unrest, our ability to integrate, manage and keep our information systems secure, our ability to realize the anticipated benefits of acquisitions, and changes in law or developments with respect to any litigation relating to the Company, including various other matters, many of which are beyond our control.
Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on any forward-looking statement as a prediction of future events. We expressly disclaim any obligation or undertaking, and we do not intend to release publicly any updates or changes in our expectations concerning the forward-looking statements or any changes in events, conditions or circumstances upon which any forward-looking statement may be based, except as required by law.
# # #
Document and Entity Information |
Apr. 14, 2021 |
---|---|
Cover [Abstract] | |
Entity Registrant Name | AMEDISYS INC |
Amendment Flag | false |
Entity Central Index Key | 0000896262 |
Document Type | 8-K |
Document Period End Date | Apr. 14, 2021 |
Entity File Number | 0-24260 |
Entity Incorporation State Country Code | DE |
Entity Tax Identification Number | 11-3131700 |
Entity Address, Address Line One | 3854 American Way |
Entity Address, Address Line Two | Suite A |
Entity Address, City or Town | Baton Rouge |
Entity Address, State or Province | LA |
Entity Address, Postal Zip Code | 70816 |
City Area Code | (225) 292-2031 or (800) |
Local Phone Number | 467-2662 |
Written Communications | false |
Soliciting Material | false |
Pre Commencement Tender Offer | false |
Pre Commencement Issuer Tender Offer | false |
Security 12b Title | Common Stock, par value $0.001 per share |
Trading Symbol | AMED |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |
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end